RecruitingNAINTERVENTIONAL

Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

This study is for people with metastatic triple-negative breast cancer who are starting their first treatment. It's investigating whether using a special digital health platform called CUREETY TECHCARE, alongside their usual medical care, makes a difference. The researchers want to know if the platform improves patients' quality of life, reduces hospital visits, and potentially helps them live longer. Half the participants will use the CUREETY TECHCARE platform, where they'll answer questions about their symptoms. The platform will then offer advice, and their medical team will also keep an eye on their progress. The other half will receive only standard care, allowing scientists to compare the experiences of both groups.

At a glance

Status

Recruiting

Phase

Sponsor

UNICANCER

Enrolment target

472

Start

25 Jul 2024

Estimated completion

02 Sep 2028

Metastatic Triple-Negative Breast Carcinoma

What is this study about?

This research study is about helping people who have a type of breast cancer known as metastatic triple-negative breast cancer. 'Metastatic' means the cancer has spread from its original site, and 'triple-negative' describes a specific kind of breast cancer that doesn't have certain hormone receptors. The study is particularly for patients who are just beginning their first treatment for this condition.

The main idea is to see if adding a digital health platform called CUREETY TECHCARE to the usual medical care can make a positive difference. This platform is designed to allow patients to share information about their symptoms from home. The researchers will compare people who use this platform with those who only receive standard care. They are hoping to find out if using CUREETY TECHCARE can improve how patients feel day-to-day (their quality of life), lead to fewer hospital visits, and even potentially help them live longer.

Key takeaways

This study evaluates a digital platform for breast cancer monitoring.
It aims to improve quality of life and potentially reduce hospital visits.
Compares digital monitoring with standard care for metastatic breast cancer.
Patients use a smartphone/computer to report symptoms.
Your standard cancer treatment will not change.
You can leave the study at any time without affecting your care.

Who may be eligible?

To join this study, you need to be an adult, at least 18 years old, and have been diagnosed with metastatic triple-negative breast cancer. You must be about to start your very first treatment for this stage of cancer. It's also important that your doctors believe you have a life expectancy of more than six months and that you are generally well enough to manage day-to-day activities.

You should have access to a computer, tablet, or smartphone with internet and be comfortable using it to answer questions about your health. You also need to be covered by some form of health insurance.

You cannot join if you are already taking part in another study that uses telemonitoring, or if your doctor thinks you wouldn't be able to use the digital platform for physical or mental health reasons. People who are under legal guardianship or deprived of their liberty cannot take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have metastatic triple-negative breast cancer?
Are you starting your first treatment for this cancer?
Do you have access to a device with internet (computer, tablet, or smartphone)?
Are you able and willing to answer online questions about your health?
Are you not in another study that uses digital health monitoring?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you'll either be asked to use the CUREETY TECHCARE digital platform or to continue with your standard medical care. If you're in the group using the platform, you'll regularly answer questions online about your symptoms and how you're feeling. The platform will then give you advice, and your medical team will also check your information and get in touch if needed.

Throughout the study, regardless of which group you are in, the research team will collect information about your health and treatment. This will include filling out some questionnaires about your quality of life at the beginning and then periodically throughout the study. The study aims to follow participants over multiple treatment lines, which means for as long as you are receiving treatment. There are no extra medications given as part of this study; it's about how care is monitored.

Potential risks and benefits

Participating in this study might offer potential benefits, such as improved quality of life, fewer hospital stays, and potentially better overall health through enhanced symptom monitoring. However, it's also possible that using the platform won't bring any direct benefits, or that it might require some extra time and effort to use. As with any study, there's always a small chance of unforeseen risks, though none are expected with this monitoring platform. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (51)

Institut de Cancérologie des Hauts-de-France (ICHF)
Verified postcode
Arras, France· Not yet recruiting
Centre Hospitalier d'Auxerre
Verified postcode
Auxerre, France· Not yet recruiting
Sainte Catherine - Institut du Cancer Avignon Provence
Verified postcode
Avignon, France· Recruiting
CH Aunay-Bayeux
Verified postcode
Bayeux, France· Not yet recruiting
Centre Hospitalier Simone Veil de Beauvais
Verified postcode
Beauvais, France· Recruiting
ICHF - Centre Pierre Curie
Verified postcode
Beuvry, France· Not yet recruiting
Hôpital Simone Veil de Blois
Verified postcode
Blois, France· Not yet recruiting
Polyclinique bordeaux nord
Verified postcode
Bordeaux, France· Recruiting
Centre Hospitalier Fleyriat
Verified postcode
Bourg-en-Bresse, France· Not yet recruiting
Centre de Cancérologie Privé de Caen Maurice Tubiana
Verified postcode
Caen, France· Not yet recruiting
Centre Francois Baclesse
Verified postcode
Caen, France· Not yet recruiting
Centre hospitalier de Carcasonne
Verified postcode
Carcassonne, France· Recruiting

Common questions

What is 'telemonitoring'?

Telemonitoring means using digital tools, like an app or website, to keep track of your health from a distance, often from your home.

What is 'metastatic triple-negative breast cancer'?

It's a type of breast cancer where the cancer has spread to other parts of the body, and it doesn't have certain features (receptors) that some other breast cancers do.

Will I get different cancer treatment if I join this study?

No, you will receive your standard cancer treatment as usual. This study is about how your care is monitored, not about giving new treatments.

What happens if I use the platform and feel unwell?

The platform is designed to give advice based on your symptoms, and your medical team will also be able to review your information and contact you if they need to.

How long will I be in the study?

You will be followed throughout your treatments for metastatic breast cancer, over potentially multiple lines of therapy.

How to find out more

Adeline POITOU

a-poitou@unicancer.fr +33658435894 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.